Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tuning method could help cochlear implant users hear better in noise

NCT ID NCT06737185

Recruiting now Symptom relief Sponsor: MED-EL Elektromedizinische Geräte GesmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two methods for tuning cochlear implants: a standard tonotopic-based setting (FS4T) and a new setting adjusted by an evolutionary algorithm (EAFS4T). Researchers want to see which one helps 22 adults with hearing loss understand speech better, especially in noisy places. Participants will test both settings and report which works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cochlear implant tuning software (FS4T and EAFS4T)
What this could lead to
If successful, this could lead to a better way to program cochlear implants, helping users hear speech more clearly in noisy environments.
What could go wrong
This is a small, early study with only 22 participants, so results may not apply to everyone. The improvement might be small or not noticeable in daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SENSORINEURAL HEARING LOSS, BILATERAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hearing Loss, Sensorineural sensorineural hearing loss disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SENSORINEURAL HEARING LOSS, BILATERAL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU

    RECRUITING

    Dijon, 21000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.